Tandem Diabetes Care/$TNDM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tandem Diabetes Care
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Ticker
$TNDM
Sector
Primary listing
Employees
2,650
Headquarters
Website
TNDM Metrics
BasicAdvanced
$837M
-
-$3.10
1.47
-
Price and volume
Market cap
$837M
Beta
1.47
52-week high
$44.76
52-week low
$9.98
Average daily volume
2.5M
Financial strength
Current ratio
2.443
Quick ratio
1.763
Long term debt to equity
325.638
Total debt to equity
340.56
Interest coverage (TTM)
-12.42%
Profitability
EBITDA (TTM)
-75.894
Gross margin (TTM)
52.55%
Net profit margin (TTM)
-20.51%
Operating margin (TTM)
-9.29%
Effective tax rate (TTM)
-1.50%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-6.41%
Return on equity (TTM)
-111.91%
Valuation
Price to revenue (TTM)
0.819
Price to book
6.28
Price to tangible book (TTM)
6.28
Price to free cash flow (TTM)
-16.022
Free cash flow yield (TTM)
-6.24%
Free cash flow per share (TTM)
-0.773
Growth
Revenue change (TTM)
25.84%
Earnings per share change (TTM)
48.18%
3-year revenue growth (CAGR)
9.37%
10-year revenue growth (CAGR)
32.64%
3-year earnings per share growth (CAGR)
145.37%
10-year earnings per share growth (CAGR)
-20.53%
What the Analysts think about TNDM
Analyst ratings (Buy, Hold, Sell) for Tandem Diabetes Care stock.
Bulls say / Bears say
The FDA approved Tandem’s Control-IQ+ algorithm for adults with type 2 diabetes in February 2025, opening up a larger market and leading to a 7% stock surge at the time (Reuters)
For Q1 2025, revenue rose 21.6% year-over-year to $234.4 million, beating analyst forecasts of $220.2 million and showing strong demand for Tandem insulin delivery systems (Reuters)
A major trial published in the New England Journal of Medicine found Control-IQ+ reduced hemoglobin A1c by 0.9% versus 0.3% in the control group for type 2 diabetes, supporting the clinical effectiveness of Tandem’s automated insulin delivery technology (NEJM)
Tandem announced a voluntary device correction in August 2025 for certain t:slim X2 pumps that have a speaker malfunction, which caused the stock to drop 26.1% in one day to its lowest level in over seven years, raising safety concerns (Reuters)
The CMS proposal released July 1, 2025, to include insulin pumps in a competitive bidding program and to cap Medicare reimbursement rates could put pricing pressure on Tandem, with TNDM shares falling 9.6% after the announcement (Reuters)
In Q1 2025, Tandem’s adjusted EPS was −$0.66, missing the consensus estimate of −$0.61, pointing to ongoing profitability issues despite revenue growth (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
TNDM Financial Performance
Revenues and expenses
TNDM Earnings Performance
Company profitability
TNDM News
AllArticlesVideos
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Business Wire3 weeks ago
Tandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Business Wire3 weeks ago
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tandem Diabetes Care stock?
Tandem Diabetes Care (TNDM) has a market cap of $837M as of September 05, 2025.
What is the P/E ratio for Tandem Diabetes Care stock?
The price to earnings (P/E) ratio for Tandem Diabetes Care (TNDM) stock is 0 as of September 05, 2025.
Does Tandem Diabetes Care stock pay dividends?
No, Tandem Diabetes Care (TNDM) stock does not pay dividends to its shareholders as of September 05, 2025.
When is the next Tandem Diabetes Care dividend payment date?
Tandem Diabetes Care (TNDM) stock does not pay dividends to its shareholders.
What is the beta indicator for Tandem Diabetes Care?
Tandem Diabetes Care (TNDM) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.